Context Therapeutics - Cash runway extended to Q124
Management has announced that Context Therapeutics will focus its R&D efforts on onapristone extended release (ONA-XR) in the ELONA trial along...
661 Views
Context Therapeutics - Anticipating a catalyst rich Q422
Context Therapeutics’ Q222 results provided an update on the company’s operating performance and pipeline. Operating losses of $4.0m, increased...
663 Views
Context Therapeutics - Promising combination therapy for ONA-XR
Context Therapeutics announced plans to collaborate with the Menarini Group to study ONA-XR in combination with elacestrant, an oral selective...
646 Views
Context Therapeutics - Q122 progress in line with development strategy
Context Therapeutics’ Q122 results were broadly in line with recent trends as the company progresses on its development strategy. The operating...
659 Views
Context Therapeutics - R&D webinar highlights pipeline potential
Context Therapeutics’ R&D webinar covered key takeaways from its five posters presented at the AACR Annual Meeting in April 2022. While the...
1 Views